Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Edwards Lifesciences Sapien 3 System Recall Classified Class I

Chairman & CEO of Edwards Lifesciences Corp (30-Year Financial, Insider Trades) Michael A Mussallem (insider trades) sold 22,850 shares of EW on 08/22/2019 at an average price of $216.7 a share.

Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5 million of Shares

Edwards Lifesciences stock dipped Thursday after the FDA recalled the company's heart-valve replacement, or TAVR, system following several injuries and a patient death during implantation.

This IBD 50 Stock Is Facing An FDA Recall — Will It Hurt Recent Gains?

The Food and Drug Administration reported Edwards Lifesciences (NYSE: EW) has recalled Sapien 3 Ultra delivery system due to burst balloons during surgery.

Edwards Lifesciences Shares Fall As FDA Reports Recall Of Sapien 3 Ultra

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Why Is Edwards Lifesciences (EW) Up 3.2% Since Last Earnings Report?

DexCom

West Pharmaceutical Services

The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.

Forget the Inverted Yield Curve, These 3 Stocks Just Hit All-Time Highs

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

Medtronic

Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.

Skip Open-Heart Surgery: TAVR OK'd In Healthier Patients; Stocks Pop

Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Edwards Lifesciences (EW) Now

Abbott Labs

Baxter

Becton, Dickinson and Co.

Boston Scientific

Illumina

Intuitive Surgical

Johnson & Johnson

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

As of late, it has definitely been a great time to be an investor in Edwards Lifesciences Corporation (EW).

Edwards Lifesciences Corporation (EW) Shares March Higher, Can It Continue?

The company's great Q2 results and increase to its full-year 2019 outlook are making investors happy.

Why Edwards Lifesciences Stock Is Jumping Today

EW beat in Q2 on sales and on adjusted EPS, and raised full-year guidance.

Edwards Lifesciences Beats, Raises And Surges: Analysis

The artificial-heart valve maker delivered another impressive performance in Q2.

Edwards Lifesciences Boosts Outlook After Posting Strong Q2 Earnings

Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q2 2019 Results - Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.76% and 4.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Q2 Earnings and Revenues Top Estimates

Edwards Lifesciences reported income of $1.38 per share and $1.09 billion in sales for the quarter ended June 30. A year ago, Edwards earnings were $1.24 a share on $943.7 million in sales.

This Big Cap 20 Stock Just Beat Forecasts And Raised Its Guidance

Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.

What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?

Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 22,850 shares of EW on 07/09/2019 at an average price of $189.14 a share.

Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $4.3 million of Shares

Shares of Edwards Lifesciences (EW) decline post product recall news.

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

Eli Lilly

Merck

Health care stocks floundered Wednesday ahead of the Democratic presidential debate and after President Donald Trump signed an order requiring hospitals to disclose their prices upfront.

Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate

A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.

Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam

Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?

ABIOMED

HCA Healthcare

The health care sector should benefit from a shift towards more defensive names in 2019.

Top 5 Health Care Stocks of 2018 by Performance

While much of the healthcare sector is stumbling or even crumbling, Edwards is sailing along, up 29% yoy.

News for Edwards Lifesciences Stock (EW)